CEO Albert Bourla’s Take on Pfizer Inc. (PFE)

Pfizer Inc. (NYSE:PFE) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On.

On May 20, 2026, Pfizer Inc. (NYSE:PFE) CEO Albert Bourla said on “In Good Company” that pandemic-era urgency allowed an eight-month COVID vaccine timeline. He said that regulators and governments “reverted to more conservative” approaches afterward. There was a sharp reversal, with COVID revenue falling from $56 billion in 2022 to about $6 billion more recently. Bourla described the swing as damaging to internal confidence while crediting a “resilience culture” for recovery.

Bourla said the company invested over $80 billion in acquisitions, including a roughly $40+ billion Seagen deal. He called its antibody drug conjugates a precision cancer-targeting platform with 4 marketed drugs and 13 in development.

CEO Albert Bourla's Take on Pfizer Inc. (PFE)

Turning to competition, he warned China could surpass the US in early-stage drug discovery within one to two years with faster speed and lower costs.

On strategy, Bourla said Pfizer Inc. (NYSE:PFE) rearranged R&D to improve focus while stressing culture over strategy, stating it “lifts the performance of an entire organization.”

Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products worldwide.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1